Form 4 for ZBIO Zenas BioPharma, Inc.
Accepted 2024-09-18 00:00:00 ET · period of report 2024-09-16 · accession 0001104659-24-101030 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2024-09-18 | 2024-09-16 | ZBIO | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | — | +801.6K | 801.6K | New | — |
| DM | 2024-09-18 | 2024-09-16 | ZBIO | Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | 10% | C - Cnv Deriv | — | -6.96M | 0 | -100% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-09-16 | C | A | 420,271 | — | 600,906 | D | — | — | (F1) On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| 2 | Common | Common Stock | 2024-09-16 | C | A | 180,635 | — | 180,635 | D | — | — | (F1) On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| 3 | Common | Common Stock | 2024-09-16 | C | A | 200,718 | — | 801,624 | D | — | — | (F1) On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| 4 | Derivative | Series A Convertible Preferred Stock | 2024-09-16 | C | D | 1,568,480 | — | 0 | D | — · — to — | 180,635 Common Stock | (F1) On September 16, 2024, the shares of Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| 5 | Derivative | Series C Convertible Preferred Stock | 2024-09-16 | C | D | 1,742,858 | — | 0 | D | — · — to — | 200,718 Common Stock | (F3) On September 16, 2024, the shares of Series C Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |
| 6 | Derivative | Series B Convertible Preferred Stock | 2024-09-16 | C | D | 3,649,263 | — | 0 | D | — · — to — | 420,271 Common Stock | (F2) On September 16, 2024, the shares of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 8.6831-for-1 basis without payment of further consideration upon the closing of the Issuer's initial public offering. The shares have no expiration date. |